This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Viatris (VTRS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Viatris' (VTRS) Q4 earnings might have gained from the solid performance of Lipitor, Influvac, Viagra and EpiPen.
Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for Bausch Health (BHC) Q4 Earnings?
by Zacks Equity Research
An update on the IPO of Bausch+Lomb and regular top-line and bottom-line numbers will grab investors' attention when BHC reports Q4 results.
Here's How Investors Can Find Strong Medical Stocks with the Zacks ESP Screener
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
AMN Healthcare (AMN) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
AMN Healthcare's (AMN) fourth-quarter results are likely to reflect solid demand in some of the areas of its business.
Viatris (VTRS) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $15.03, moving -0.92% from the previous trading session.
Why Viatris (VTRS) Could Beat Earnings Estimates Again
by Zacks Equity Research
Viatris (VTRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Viatris (VTRS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $15.22, moving -0.26% from the previous trading session.
Viatris (VTRS) Gets FDA Nod for Generic Drug in Dry Eye Disease
by Zacks Equity Research
Viatris' (VTRS) subsidiary is the first to receive approval from the FDA to market a generic version of AbbVie's Restasis for the treatment of dry eye disease.
Viatris (VTRS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed at $15.30 in the latest trading session, marking a +1.53% move from the prior day.
Viatris (VTRS) Stock Moves -0.21%: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $14.59, moving -0.21% from the previous trading session.
Viatris (VTRS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Viatris (VTRS) closed at $14.36, marking a -1.17% move from the previous day.
Viatris (VTRS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Viatris (VTRS) closed at $15.22, marking a +1.33% move from the previous day.
Viatris (VTRS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $15.17, moving -0.98% from the previous trading session.
Pfizer (PFE) COVID Vaccine & Pill Drive Stock Up This Year
by Zacks Equity Research
Pfizer's (PFE) stock is up 38.8% this year so far, riding high on the success of its two-shot vaccine for COVID-19.
Viatris (VTRS) Beats on Q3 Earnings & Sales, Tweaks View
by Zacks Equity Research
Viatris (VTRS) beats on Q3 earnings and sales. The company raises the lower end of its annual revenue guidance.
Viatris (VTRS) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Viatris (VTRS) delivered earnings and revenue surprises of 15.12% and 3.85%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stocks' Q3 Earnings on Nov 8: VTRS, EDIT & More
by Kinjel Shah
Let us look at four drug/biotech companies, VTRS, RDUS, AXSM and EDIT, which are gearing up for their earnings release.
Theravance's (TBPH) Q3 Earnings Beat, Restructuring On Track
by Zacks Equity Research
Theravance's (TBPH) loss narrows in the third quarter of 2021 while revenues decline year over year. Stock down.
Viatris (VTRS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Viatris (VTRS) closed at $13.83, marking a +0.07% move from the previous day.
Viatris (VTRS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Viatris' (VTRS) Q3 earnings might have gained from the solid performance of Viagra, Dymista, and the Thrombosis portfolio.
Earnings Preview: Viatris (VTRS) Q3 Earnings Expected to Decline
by Zacks Equity Research
Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts See a 33% Upside in Viatris (VTRS): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Viatris (VTRS) points to a 33.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Theravance (TBPH) to Cut Workforce, Hypotension Study Fails
by Zacks Equity Research
Theravance's (TBPH) phase III study on ampreloxetine for treating symptomatic neurogenic orthostatic hypotension fails to meet goal. The company plans to cut its workforce by 75%. Stocks falls.
Why Is Viatris (VTRS) Down 3% Since Last Earnings Report?
by Zacks Equity Research
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.